Treats major depressive disorder (MDD). ANDA 208606, held by Cadila Pharms Ltd. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 208606 (Bupropion Hydrochloride), held by Cadila Pharms Ltd, was first approved by FDA on Jan 16, 2020, with 4 approved supplements and 0 published complete response letters.
Bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of bupropion hydrochloride tablets in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2020 | Original application | Approved | None posted |
| Bupropion Hydrochloride75MG · tablet;oral | Bupropion Hydrochloride | Rx |
| Bupropion Hydrochloride100MG · tablet;oral | Bupropion Hydrochloride | Rx |
| Nov 5, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 7, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 7, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 7, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 16, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters